Searched for
GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION
Sun Pharma Q2 Results: Profit falls 36% YoY to Rs 1,989 crore on exceptional chargesSun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported...- Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred ac...
- India’s drug pricing policy must balance affordability, medicine availability and pharma industry growthThe Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...
- India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: PharmexcilIndia's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driv...
- Parliamentary panel to discuss implementation of National Litigation Policy already junked by govtA parliamentary standing committee will examine the formulation and implementation of a National Litigation Policy in 2026-27, even though ...
- Cancer drug price cuts leave costly brands untouchedPrices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices ...
- Cancer care can be cheaper: 6 steps to cut drug costsIndia has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...
- Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...
- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Mankind Pharma shares key business developments from Q2 & H1 of FY27The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...
- Dr Reddy's bets on generic semaglutide, biosimilarsDr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of gene...
- DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
- Indian pharma: Unethical practices, marketing rules under lens; new review body set upThe review comes against the backdrop of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which was introduced in 2015 as a...
- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Jubilant Pharmova eyes $150 million through rupee debt sale, bankers sayJubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure a...
- NATCO Pharma subsidiary launches Carboplatin in US market to address shortagesIndian pharmaceutical company NATCO Pharma annouced the launch of Carboplatin Injection, a generic version of Paraplatin in the US market b...
- Apple names Meta veteran Scott Tucker as litigation chief in legal team shake-upApple has hired former Meta litigation chief Scott Tucker as vice president of global litigation and financial services, strengthening its ...
- Long-term investing is about looking beyond narratives, including AI: 5 large-caps with an upside potential of up to 24%As we see a recovery in the market, it is good to be cognizant of the fact that more than the narratives on the street, it is the earnings ...
Load More
